Stock listing
Prostatype Genomics Ab
Selected listing: PROGEN · OMXSTO · SEK · SE
Prostatype Genomics Ab (Stockholm:PROGEN), Health Technology. Latest release Sep 17, 2026: Prostatype Genomics AB receives approximately SEK 12.5 million…
- Ticker
- Stockholm:PROGEN
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Medical Specialties
- Exchange
- Stockholm
- Currency
- SEK
About Prostatype Genomics Ab
Prostatype Genomics Ab, trading under the ticker PROGEN, is a public company based in Sweden. Prostatype Genomics focuses on developing genomic solutions for prostate cancer management.
Latest news from Prostatype Genomics Ab
Prostatype Genomics AB receives approximately SEK 12.5 million through the exercise of warrants of series TO6
September 17, 2026
Prostatype Genomics receives commitments and letters of intent of approx. 70 percent of the exercise of warrants TO6
August 31, 2026
Prostatype Genomics AB resolves on a directed issue
August 5, 2026
Prostatype Genomics AB announces last day of trading in BTUs and first day of trading in warrants of series TO6 and TO7
August 3, 2026
Prostatype Genomics AB announces outcome in rights issue of units
July 27, 2026
Research Prostatype Genomics Ab
Prostatype Genomics Ab company profile
View the public company page for Prostatype Genomics Ab on 6ix.
Prostatype Genomics Ab news
Read company news and market updates connected to Prostatype Genomics Ab.
Prostatype Genomics Ab investor events
Find investor webinars, events, and replay context for Prostatype Genomics Ab.